Why we are nowhere near a Zika vaccine - despite millions of taxpayers’ money spent : dailymail

according to dailymail

Why we are nowhere near a Zika vaccine - despite millions of taxpayers' money spent

Why we are nowhere near a Zika vaccine - despite millions of taxpayers' money spent

Recent news articles have highlighted positive findings in experimental Zika virus pre-clinical vaccine studies in monkeys and described the start of two Zika virus vaccine trials in humans.These stories have spurred hopes that a Zika virus vaccine will be available to prevent this infection, and its secondary effects, such as abnormal fetal development.But, even with pre-clinical and early stage clinical trials underway, we still may not see a Zika vaccine licensed and approved for use in humans for years.


besides outbreaknewstoday

Kansas State University researchers develop Zika DNA vaccine

Kansas State University researchers develop Zika DNA vaccine

A research team that includes scientists with Kansas State University's Biosecurity Research Institute has developed a promising Zika virus vaccine.The vaccine, a DNA vaccine, is safer and more effective against Zika virus and could offer more affordable long-term protection, researchers said."This vaccine is a successful advancement in developing control strategies for Zika virus by creating widespread immunity in susceptible populations," said Stephen Higgs, director of the Biosecurity Research Institute.


additionally fiercepharma

Sanofi grabs $43M in U.S. government funds to advance Zika vaccine into Phase II

Sanofi grabs $43M in U.S. government funds to advance Zika vaccine into Phase II

Just months after signing on with the Walter Reed Army Institute of Research to develop a Zika vaccine, Sanofi Pasteur won a $43 million vote of confidence from the U.S. government's BARDA to advance the work.The Biomedical Advanced Research and Development Authority (BARDA) shelled out to fund Phase II development of Sanofi's candidate vaccine, dubbed Zika purified inactivated virus (ZPIV).If the Phase II testing is successful, BARDA could advance another $130 million for follow-up studies, the agency said.